Samuel Lentz to Paclitaxel
This is a "connection" page, showing publications Samuel Lentz has written about Paclitaxel.
Connection Strength
0.172
-
Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5.
Score: 0.094
-
Thigpen JT, Blessing JA, Olt G, Lentz SS, Bell J. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Sep; 90(3):581-6.
Score: 0.055
-
Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011 Oct; 202(4):481-6.
Score: 0.023